doi: 10.1161/hc3601.094304
(Circulation. 2001;104:1274.)
© 2001 American Heart Association, Inc.
Basic Science Reports |
Significance of Chymase-Dependent Angiotensin II–Forming Pathway in the Development of Vascular Proliferation
From the Departments of Pharmacology (M.N., S.T., D.J., A.Y., M.S., M.Y., M.M.) and Thoracic and Cardiovascular Surgery (M.N., A.Y., Y.S., K.K., K.A., S.S.), Osaka Medical College, and the Department of Pharmacology, Osaka City University Medical School (S.K., H.I.), Osaka, Japan.
Correspondence to Mizuo Miyazaki, MD, PhD, Department of Pharmacology, Osaka Medical College, Osaka 569-8686, Japan. E-mail pha010{at}art.osaka-med.ac.jp
Background— Vascular tissues of humans and dogs contain chymase as an angiotensin II–forming enzyme. In this study, we investigated whether chymase-dependent angiotensin II formation plays a crucial role in the development of vascular proliferation in dog grafted veins.
Methods and Results— The right external jugular vein of dogs was grafted to the ipsilateral carotid artery. As a control group, the right external jugular veins in dogs that had not received grafts were used. In the chymase inhibitor–treated group, the vein was infiltrated with 10 µmol/L Suc-Val-Pro-PheP(OPh)2 and was grafted to the carotid artery. In the placebo-treated group, ACE activity in the grafted veins was significantly lower than that in the control veins up to 7 days after the operation, whereas chymase activity was increased significantly. After 7 days, the mRNA levels of collagen I, collagen III, and fibronectin, all of which are induced by an increase of angiotensin II action, were significantly increased in the grafted veins, and the intima-media ratio of the grafted veins was also increased. In the chymase inhibitor–treated group, the chymase activity in the grafted veins 7 days after the operation was suppressed to 12.1%. The elevated mRNA levels of fibronectin, collagen I, and collagen III in the grafted veins were significantly suppressed by treatment with the chymase inhibitor, and the intima-media ratio was also decreased significantly.
Conclusions— We demonstrate for the first time that chymase-dependent angiotensin II formation plays an important role in the development of vascular proliferation in the grafted veins.
Key Words: angiotensin • enzymes • chymase • grafting
This article has been cited by other articles:
 |
|
 |
|
  W. W. Raymond, S. Su, A. Makarova, T. M. Wilson, M. C. Carter, D. D. Metcalfe, and G. H. Caughey {alpha}2-Macroglobulin Capture Allows Detection of Mast Cell Chymase in Serum and Creates a Reservoir of Angiotensin II-Generating Activity J. Immunol., May 1, 2009; 182(9): 5770 - 5777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Caughey, J. Beauchamp, D. Schlatter, W. W. Raymond, N. N. Trivedi, D. Banner, H. Mauser, and J. Fingerle Guinea Pig Chymase Is Leucine-specific: A NOVEL EXAMPLE OF FUNCTIONAL PLASTICITY IN THE CHYMASE/GRANZYME FAMILY OF SERINE PEPTIDASES J. Biol. Chem., May 16, 2008; 283(20): 13943 - 13951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Noack, L Balleisen, P Valent, and H-P Horny Angiosarcoma of bone marrow with unusual expression of chymase: diagnosis in a trephine biopsy specimen J. Clin. Pathol., October 1, 2007; 60(10): 1183 - 1183. [Full Text] [PDF]
|
|
|
|
|
|
L. de Garavilla, M. N. Greco, N. Sukumar, Z.-W. Chen, A. O. Pineda, F. S. Mathews, E. Di Cera, E. C. Giardino, G. I. Wells, B. J. Haertlein, et al. A Novel, Potent Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase: MOLECULAR MECHANISMS AND ANTI-INFLAMMATORY ACTIVITY IN VIVO J. Biol. Chem., May 6, 2005; 280(18): 18001 - 18007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jin, H. Ueda, S. Takai, Y. Okamoto, M. Muramatsu, M. Sakaguchi, N. Shibahara, Y. Katsuoka, and M. Miyazaki Effect of Chymase Inhibition on the Arteriovenous Fistula Stenosis in Dogs J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1024 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jin, S. Takai, M. Sakaguchi, Y. Okamoto, M. Muramatsu, and M. Miyazaki An Antiarrhythmic Effect of a Chymase Inhibitor after Myocardial Infarction J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 490 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A Doggrell and J. C Wanstall Vascular chymase: pathophysiological role and therapeutic potential of inhibition Cardiovasc Res, March 1, 2004; 61(4): 653 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Liu, G. Bhattacharjee, W. Boisvert, R. Dilley, and T. Edgington In Vivo Interrogation of the Molecular Display of Atherosclerotic Lesion Surfaces Am. J. Pathol., November 1, 2003; 163(5): 1859 - 1871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jin, S. Takai, M. Yamada, M. Sakaguchi, K. Kamoshita, K. Ishida, Y. Sukenaga, and M. Miyazaki Impact of chymase inhibitor on cardiac function and survival after myocardial infarction Cardiovasc Res, November 1, 2003; 60(2): 413 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Chen, M. Iwai, L. Wu, J. Suzuki, L.-J. Min, T. Shiuchi, T. Sugaya, H.-W. Liu, T.-X. Cui, and M. Horiuchi Important Role of Nitric Oxide in the Effect of Angiotensin-Converting Enzyme Inhibitor Imidapril on Vascular Injury Hypertension, October 1, 2003; 42(4): 542 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Takai, H. Sakonjo, K. Fukuda, D. Jin, M. Sakaguchi, K. Kamoshita, K. Ishida, Y. Sukenaga, and M. Miyazaki A Novel Chymase Inhibitor, 2-(5-Formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[{3,4-dioxo-1-phenyl-7-(2-pyridyloxy)}-2-heptyl]acetamide (NK3201), Suppressed Intimal Hyperplasia after Balloon Injury J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 841 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tsunemi, S. Takai, M. Nishimoto, A. Yuda, D. Jin, M. Sakaguchi, Y. Sawada, K. Asada, K. Kondo, S. Sasaki, et al. Lengthy suppression of vascular proliferation by a chymase inhibitor in dog grafted veins J. Thorac. Cardiovasc. Surg., September 1, 2002; 124(3): 621 - 625. [Full Text] [PDF]
|
|